Global Oncolytic Virus Immunotherapy Market
Description
MARKET SCOPE:
The global Oncolytic Virus Immunotherapy market is projected to grow significantly, registering a CAGR of 12.6% during the forecast period (2024 – 2032).
Oncolytic virus immunotherapy represents a form of cancer treatment that harnesses the power of viruses to selectively target and eliminate cancer cells. In contrast to conventional chemotherapy or radiation therapy, which can impact both healthy and cancerous cells throughout the body, oncolytic viruses are specifically engineered to replicate within and destroy cancer cells while sparing normal, healthy cells. The fundamental concept behind oncolytic virus immunotherapy involves the utilization of viruses that have been modified to infect and replicate selectively within cancer cells. These modified viruses can exert their effects by directly lysing (destroying) cancer cells or by triggering the immune system to recognize and attack cancer cells. Furthermore, the viral replication within cancer cells can result in the release of tumor-associated antigens, prompting an immune response against the cancer.
To enhance safety and specificity for cancer cells, the oncolytic viruses employed in this therapy are often engineered. Modifications can be made to enable these viruses to preferentially replicate in cancer cells with specific genetic mutations or alterations characteristic of tumor cells. While some oncolytic viruses are naturally occurring, others are genetically modified versions of existing viruses. Various oncolytic viruses, such as herpes simplex virus, adenovirus, vaccinia virus, and others, have been extensively studied and developed for clinical applications. Oncolytic virus immunotherapy is regarded as a promising approach in the realm of cancer treatment, with ongoing investigations in diverse clinical trials targeting different types of cancers.
MARKET OVERVIEW:
Driver: FDA approval is driving the market growth.
While the trajectory of research and development activities is expected to evolve during the forecast period, approvals from the FDA for various oncolytic virus immunotherapies are anticipated to propel the oncolytic virus immunotherapy market. Currently, numerous oncolytic viruses are progressing through pre-clinical and clinical development stages. Moreover, recent research findings suggest that the therapeutic potential of oncolytic viruses extends beyond melanomas. Over the last decade, oncolytic virus immunotherapy has gained significant traction as a groundbreaking advancement in cancer therapies, and this trend is poised to persist in the forecast period. Additionally, oncolytic virus immunotherapy addresses inherent challenges associated with traditional therapies such as radiotherapy and chemotherapy, contributing to the global surge in demand. Oncolytic viruses are expected to play a transformative role in oncologic care as therapeutic adjuncts, further fueling the demand for oncolytic virus immunotherapy. Furthermore, oncolytic virus immunotherapies are positioned to tackle the critical issue of acquired and primary immunotherapeutic resistance.
Opportunities: The rising number of clinical studies in oncolytic virus is expected to pave the way for market growth in the upcoming years.
The increasing volume of clinical studies in oncolytic virus therapies and the growing approvals from the FDA for various oncolytic virus immunotherapies are expected to boost the demand for oncolytic virus immunotherapy software in the forecast period. The market is witnessing growth driven by the availability of oncolytic virus immunotherapy drugs for melanoma therapeutics, along with a well-defined pipeline for breast cancer. However, long-term market prospects are hindered by diminishing efficacy due to the presence of circulating antibodies. Additionally, poor intratumoral penetration by oncolytic viruses poses a challenge to market growth. Nevertheless, emerging market trends, including a rise in the number of clinical trials and increased research funding, may present significant opportunities for leading players in the market.
COVID IMPACT:
The onset of the COVID-19 pandemic is anticipated to exert minimal impact on the overall growth trajectory of the global oncolytic virus immunotherapy market. Research and development endeavors persistently attract significant attention as investigators explore the potential utilization of oncolytic virus immunotherapy tools to mitigate the spread of COVID-19 infection. The urgent necessity for developing an efficacious vaccine against the novel coronavirus has heightened research activities. Consequently, the COVID-19 pandemic has spurred increased efforts towards the exploration of oncolytic virus immunotherapy in the context of addressing the challenges posed by the virus.
SEGMENTATION ANALYSIS:
The Adenovirus is anticipated to grow significantly during the forecast period.
Adenovirus exhibits the ability to infect and eliminate cancer cells without causing harm to normal cells, making it the most effective agent in gene-targeted oncolytic virus therapy (GTOVT) due to its favorable characteristics. Furthermore, the oncolytic adenovirus elicits an anti-cancer immune response, enhancing its anti-cancer effectiveness, even in addressing metastatic aspects. This, in turn, is anticipated to drive the growth of the loaded cargo segment in the forecast period.
The Non-small Cell Lung Cancer (NSCLC) is anticipated to grow significantly during the forecast period.
This segment is attributed to the fact that NSCLC is the predominant form of lung cancer, constituting the majority of lung cancer diagnoses. Various risk factors such as exposure to smoking, hazardous materials, air pollution, and a family history of lung cancer contribute to the prevalence of NSCLC. The other segment, encompassing ovarian cancer and head & neck squamous cell carcinoma, is expected to experience significant growth due to the rising incidence of ovarian cancer and head & neck squamous cell carcinoma worldwide.
REGIONAL ANALYSIS:
The North American region is set to witness significant growth during the forecast period.
The growth of the oncolytic virus immunotherapy market in North America is attributed to the increasing incidence of cancer cases in the region. Furthermore, the substantial presence of major manufacturers and vendors in the United States and Canada is expected to significantly contribute to the regional market's success. Generous government funding for research activities focused on the development of novel therapies for cancer treatment and the creation of new drugs is anticipated to boost the size of the oncolytic virus immunotherapy market in North America. Evidently, the oncolytic virus immunotherapy industry is poised for substantial growth prospects in the sub-continent, driven by a significant proportion of sponsorships from cancer drug molecule manufacturers in the region.
COMPETITIVE ANALYSIS
The global Oncolytic Virus Immunotherapy market is reasonably competitive with mergers, acquisitions, and product launches. See some of the major key players in the market.
Siga Technologies
Merck & Co., Inc. (Viralytics Limited)
Shanghai Sunway Biotech Co., Ltd.
TILT Biotherapeutics
Oncorus, Inc.
Replimune Group, Inc.
Oncolys BioPharma, Inc.
Sorrento Therapeutics, Inc.
Oncolytics Biotech, Inc.
SillaJen, Inc. a
SCOPE OF THE REPORT
By Type
It provides a technological development map over time to understand the industry’s growth rate and indicates how the Oncolytic Virus Immunotherapy market is evolving.
The report offers a dynamic method to various factors that drive or restrain the growth of the market and specifies which Oncolytic Virus Immunotherapy submarket will be the main driver of the overall market from 2024 to 2032.
It renders a definite analysis of changing competitive dynamics and stipulates the leading players and what are their prospects over the forecast period.
It builds a nine-year estimate based on how the market is predicted to grow and shows what will market shares of the global region change by 2032 and which country will lead the market in 2032.
The global Oncolytic Virus Immunotherapy market is projected to grow significantly, registering a CAGR of 12.6% during the forecast period (2024 – 2032).
Oncolytic virus immunotherapy represents a form of cancer treatment that harnesses the power of viruses to selectively target and eliminate cancer cells. In contrast to conventional chemotherapy or radiation therapy, which can impact both healthy and cancerous cells throughout the body, oncolytic viruses are specifically engineered to replicate within and destroy cancer cells while sparing normal, healthy cells. The fundamental concept behind oncolytic virus immunotherapy involves the utilization of viruses that have been modified to infect and replicate selectively within cancer cells. These modified viruses can exert their effects by directly lysing (destroying) cancer cells or by triggering the immune system to recognize and attack cancer cells. Furthermore, the viral replication within cancer cells can result in the release of tumor-associated antigens, prompting an immune response against the cancer.
To enhance safety and specificity for cancer cells, the oncolytic viruses employed in this therapy are often engineered. Modifications can be made to enable these viruses to preferentially replicate in cancer cells with specific genetic mutations or alterations characteristic of tumor cells. While some oncolytic viruses are naturally occurring, others are genetically modified versions of existing viruses. Various oncolytic viruses, such as herpes simplex virus, adenovirus, vaccinia virus, and others, have been extensively studied and developed for clinical applications. Oncolytic virus immunotherapy is regarded as a promising approach in the realm of cancer treatment, with ongoing investigations in diverse clinical trials targeting different types of cancers.
MARKET OVERVIEW:
Driver: FDA approval is driving the market growth.
While the trajectory of research and development activities is expected to evolve during the forecast period, approvals from the FDA for various oncolytic virus immunotherapies are anticipated to propel the oncolytic virus immunotherapy market. Currently, numerous oncolytic viruses are progressing through pre-clinical and clinical development stages. Moreover, recent research findings suggest that the therapeutic potential of oncolytic viruses extends beyond melanomas. Over the last decade, oncolytic virus immunotherapy has gained significant traction as a groundbreaking advancement in cancer therapies, and this trend is poised to persist in the forecast period. Additionally, oncolytic virus immunotherapy addresses inherent challenges associated with traditional therapies such as radiotherapy and chemotherapy, contributing to the global surge in demand. Oncolytic viruses are expected to play a transformative role in oncologic care as therapeutic adjuncts, further fueling the demand for oncolytic virus immunotherapy. Furthermore, oncolytic virus immunotherapies are positioned to tackle the critical issue of acquired and primary immunotherapeutic resistance.
Opportunities: The rising number of clinical studies in oncolytic virus is expected to pave the way for market growth in the upcoming years.
The increasing volume of clinical studies in oncolytic virus therapies and the growing approvals from the FDA for various oncolytic virus immunotherapies are expected to boost the demand for oncolytic virus immunotherapy software in the forecast period. The market is witnessing growth driven by the availability of oncolytic virus immunotherapy drugs for melanoma therapeutics, along with a well-defined pipeline for breast cancer. However, long-term market prospects are hindered by diminishing efficacy due to the presence of circulating antibodies. Additionally, poor intratumoral penetration by oncolytic viruses poses a challenge to market growth. Nevertheless, emerging market trends, including a rise in the number of clinical trials and increased research funding, may present significant opportunities for leading players in the market.
COVID IMPACT:
The onset of the COVID-19 pandemic is anticipated to exert minimal impact on the overall growth trajectory of the global oncolytic virus immunotherapy market. Research and development endeavors persistently attract significant attention as investigators explore the potential utilization of oncolytic virus immunotherapy tools to mitigate the spread of COVID-19 infection. The urgent necessity for developing an efficacious vaccine against the novel coronavirus has heightened research activities. Consequently, the COVID-19 pandemic has spurred increased efforts towards the exploration of oncolytic virus immunotherapy in the context of addressing the challenges posed by the virus.
SEGMENTATION ANALYSIS:
The Adenovirus is anticipated to grow significantly during the forecast period.
Adenovirus exhibits the ability to infect and eliminate cancer cells without causing harm to normal cells, making it the most effective agent in gene-targeted oncolytic virus therapy (GTOVT) due to its favorable characteristics. Furthermore, the oncolytic adenovirus elicits an anti-cancer immune response, enhancing its anti-cancer effectiveness, even in addressing metastatic aspects. This, in turn, is anticipated to drive the growth of the loaded cargo segment in the forecast period.
The Non-small Cell Lung Cancer (NSCLC) is anticipated to grow significantly during the forecast period.
This segment is attributed to the fact that NSCLC is the predominant form of lung cancer, constituting the majority of lung cancer diagnoses. Various risk factors such as exposure to smoking, hazardous materials, air pollution, and a family history of lung cancer contribute to the prevalence of NSCLC. The other segment, encompassing ovarian cancer and head & neck squamous cell carcinoma, is expected to experience significant growth due to the rising incidence of ovarian cancer and head & neck squamous cell carcinoma worldwide.
REGIONAL ANALYSIS:
The North American region is set to witness significant growth during the forecast period.
The growth of the oncolytic virus immunotherapy market in North America is attributed to the increasing incidence of cancer cases in the region. Furthermore, the substantial presence of major manufacturers and vendors in the United States and Canada is expected to significantly contribute to the regional market's success. Generous government funding for research activities focused on the development of novel therapies for cancer treatment and the creation of new drugs is anticipated to boost the size of the oncolytic virus immunotherapy market in North America. Evidently, the oncolytic virus immunotherapy industry is poised for substantial growth prospects in the sub-continent, driven by a significant proportion of sponsorships from cancer drug molecule manufacturers in the region.
COMPETITIVE ANALYSIS
The global Oncolytic Virus Immunotherapy market is reasonably competitive with mergers, acquisitions, and product launches. See some of the major key players in the market.
Siga Technologies
- In January 2022, Siga Technologies has unveiled a preclinical partnership with Bioarchitech to explore the development of cancer treatment immunotherapy. This collaborative research focuses on examining the potential of TPOXX (tecovirimat) when combined with Bioarchitech's exclusive vaccinia-based immunotherapy platform. The platform employs engineered antibodies and other proteins integrated into the oncolytic virus genome.
Merck & Co., Inc. (Viralytics Limited)
Shanghai Sunway Biotech Co., Ltd.
TILT Biotherapeutics
Oncorus, Inc.
Replimune Group, Inc.
Oncolys BioPharma, Inc.
Sorrento Therapeutics, Inc.
Oncolytics Biotech, Inc.
SillaJen, Inc. a
SCOPE OF THE REPORT
By Type
- Vaccinia Virus
- Herpes Simplex Virus
- Reovirus
- Adenovirus
- Others
- Intravenous
- Intratumoral
- Other
- Non-small Cell Lung Cancer (NSCLC)
- Melanoma
- Breast Cancer
- Pancreatic Cancer
- Others
- Clinic
- Hospital
- Cancer Research Institutes
- Others
- North America (the United States & Canada)
- Europe (Germany, UK, France, Spain, Italy, and the Rest of Europe)
- Asia Pacific (China, Japan, India, and Rest of Asia Pacific)
- Rest of the World (the Middle East & Africa, and Latin America)
It provides a technological development map over time to understand the industry’s growth rate and indicates how the Oncolytic Virus Immunotherapy market is evolving.
The report offers a dynamic method to various factors that drive or restrain the growth of the market and specifies which Oncolytic Virus Immunotherapy submarket will be the main driver of the overall market from 2024 to 2032.
It renders a definite analysis of changing competitive dynamics and stipulates the leading players and what are their prospects over the forecast period.
It builds a nine-year estimate based on how the market is predicted to grow and shows what will market shares of the global region change by 2032 and which country will lead the market in 2032.
Table of Contents
190 Pages
- 1. Executive Summary
- 1.1. Market Snapshot
- 1.2. Regional Analysis
- 1.3. Segment Analysis
- 2. Overview And Scope
- 2.1. Market Vision
- 2.1.1. Market Definition
- 2.2. Market Segmentation
- 3. Global Oncolytic Virus Immunotherapy Market Overview By Region: 2019 Vs 2023 Vs 2032
- 3.1. Global Oncolytic Virus Immunotherapy Market Size By Regions (2019-2023) (Usd Million)
- 3.1.1. North America Oncolytic Virus Immunotherapy Market Size By Country (2019-2023) (Usd Million)
- 3.1.2. Europe Oncolytic Virus Immunotherapy Market Size By Country (2019-2023) (Usd Million)
- 3.1.3. Asia Pacific America Oncolytic Virus Immunotherapy Market Size By Country (2019-2023) (Usd Million)
- 3.1.4. Rest Of The World Oncolytic Virus Immunotherapy Market Size By Country (2019-2023) (Usd Million)
- 3.2. Global Oncolytic Virus Immunotherapy Market Size By Regions (2024-2032) (Usd Million)
- 3.2.1. North America Oncolytic Virus Immunotherapy Market Size By Country (2024-2032) (Usd Million)
- 3.2.2. Europe Oncolytic Virus Immunotherapy Market Size By Country (2024-2032) (Usd Million)
- 3.2.3. Asia Pacific Oncolytic Virus Immunotherapy Market Size By Country (2024-2032) (Usd Million)
- 3.2.4. Rest Of The World Oncolytic Virus Immunotherapy Market Size By Country (2024-2032) (Usd Million)
- 4. Global Oncolytic Virus Immunotherapy Market Dynamics
- 4.1. Market Overview
- 4.1.1. Market Drivers
- 4.1.2. Market Restraints/ Challenges Analysis
- 4.1.3. Market Opportunities
- 4.2. Pestle Analysis
- 4.3. Porter’s Five Forces Model
- 4.3.1. Bargaining Power Of Suppliers
- 4.3.2. Bargaining Power Of Buyers
- 4.3.3. The Threat Of New Entrants
- 4.3.4. Threat Of Substitutes
- 4.3.5. Intensity Of Rivalry
- 4.4. Value Chain Analysis/Supply Chain Analysis
- 4.5. Covid-19 Impact Analysis On Global Oncolytic Virus Immunotherapy Market
- ** In – Depth Qualitative Analysis Will Be Provided In The Final Report Subject To Market
- 5. Global Oncolytic Virus Immunotherapy Market, By Type
- 5.1. Overview
- 5.2. Global Oncolytic Virus Immunotherapy Market Size By Type
- 5.3. Key Findings For Oncolytic Virus Immunotherapy Market - By Type
- 5.3.1. Gene Therapy
- 5.3.2. Rna-based Therapies
- 6. Global Oncolytic Virus Immunotherapy Market, By Route Of Administration
- 6.1. Overview
- 6.2. Key Findings For Oncolytic Virus Immunotherapy Market - By Route Of Administration
- 6.2.1. Process Development And Optimization
- 6.2.2. Manufacturing Services
- 6.2.3. Analytical And Quality Control Services
- 6.2.4. Others
- 7. Global Oncolytic Virus Immunotherapy Market, By Application
- 7.1. Overview
- 7.2. Key Findings For Oncolytic Virus Immunotherapy Market - By Application
- 7.2.1. Oncology
- 7.2.2. Genetic Disorders
- 7.2.3. Infectious Diseases
- 7.2.4. Others
- 8. Global Oncolytic Virus Immunotherapy Market, By End Users
- 8.1. Overview
- 8.2. Key Findings For Oncolytic Virus Immunotherapy Market - By End Users
- 8.2.1. Pharmaceutical Companies
- 8.2.2. Government & Academic Research Institutes
- 8.2.3. Biotech Companies
- 9. Global Oncolytic Virus Immunotherapy Market, By Region
- 9.1. Overview
- 9.2. Key Findings For Oncolytic Virus Immunotherapy Market- By Region
- 9.3. Global Oncolytic Virus Immunotherapy Market, By Type
- 9.4. Global Oncolytic Virus Immunotherapy Market, By Route Of Administration
- 9.5. Global Oncolytic Virus Immunotherapy Market, By Application
- 9.6. Global Oncolytic Virus Immunotherapy Market, By End Users
- 10. Global Oncolytic Virus Immunotherapy Market- North America
- 10.1. Overview
- 10.2. North America Oncolytic Virus Immunotherapy Market Size (2019 - 2032) (Usd Million)
- 10.3. North America Oncolytic Virus Immunotherapy Market, By Type
- 10.4. North America Oncolytic Virus Immunotherapy Market, By Route Of Administration
- 10.5. North America Oncolytic Virus Immunotherapy Market, By Application
- 10.6. North America Oncolytic Virus Immunotherapy Market, By End Users
- 10.7. North America Oncolytic Virus Immunotherapy Market Size By Countries
- 10.7.1. United States
- 10.7.2. Canada
- 11. Global Oncolytic Virus Immunotherapy Market- Europe
- 11.1. Overview
- 11.2. Europe Oncolytic Virus Immunotherapy Market Size (2019 - 2032) (Usd Million)
- 11.3. Europe Oncolytic Virus Immunotherapy Market, By Type
- 11.4. Europe Oncolytic Virus Immunotherapy Market, By Route Of Administration
- 11.5. Europe Oncolytic Virus Immunotherapy Market, By Application
- 11.6. Europe Oncolytic Virus Immunotherapy Market, By End Users
- 11.7. Europe Oncolytic Virus Immunotherapy Market Size By Countries
- 11.7.1. Germany
- 11.7.2. Uk
- 11.7.3. France
- 11.7.4. Spain
- 11.7.5. Italy
- 11.7.6. Rest Of Europe
- 12. Global Oncolytic Virus Immunotherapy Market - Asia Pacific
- 12.1. Overview
- 12.2. Asia Pacific Oncolytic Virus Immunotherapy Market Size (2019 - 2032) (Usd Million)
- 12.3. Asia Pacific Oncolytic Virus Immunotherapy Market, By Type
- 12.4. Asia Pacific Oncolytic Virus Immunotherapy Market, By Route Of Administration
- 12.5. Asia Pacific Oncolytic Virus Immunotherapy Market, By Application
- 12.6. Asia Pacific Oncolytic Virus Immunotherapy Market, By End Users
- 12.7. Asia Pacific Oncolytic Virus Immunotherapy Market Size By Countries
- 12.7.1. China
- 12.7.2. Japan
- 12.7.3. India
- 12.7.4. Rest Of Asia Pacific
- 13. Global Oncolytic Virus Immunotherapy Market- Rest Of World
- 13.1. Overview
- 13.2. Rest Of World Oncolytic Virus Immunotherapy Market Size (2019 - 2032) (Usd Million)
- 13.3. Rest Of World Oncolytic Virus Immunotherapy Market, By Type
- 13.4. Rest Of World Oncolytic Virus Immunotherapy Market, By Route Of Administration
- 13.5. Rest Of World Oncolytic Virus Immunotherapy Market, By Application
- 13.6. Rest Of World Oncolytic Virus Immunotherapy Market, By End Users
- 13.7. Rest Of World Oncolytic Virus Immunotherapy Market Size By Regions
- 13.7.1. Middle East & Africa
- 13.7.2. Latin America
- 14. Global Oncolytic Virus Immunotherapy Market- Competitive Landscape
- 14.1. Key Strategies Adopted By The Leading Players
- 14.2. Recent Developments
- 14.2.1. Investments & Expansions
- 14.2.2. New End-user Launches
- 14.2.3. Mergers & Acquisitions
- 14.2.4. Agreements, Joint Ventures, And Partnerships
- 15. Global Oncolytic Virus Immunotherapy Market- Company Profiles
- 15.1. Siga Technologies
- 15.1.1. Company Overview
- 15.1.2. Financial Overview
- 15.1.3. Product Offered
- 15.1.4. Key Developments
- 15.2. Amgen, Inc.
- 15.3. Merck & Co., Inc. (Viralytics Limited)
- 15.4. Shanghai Sunway Biotech Co., Ltd.
- 15.5. Tilt Biotherapeutics
- 15.6. Oncorus, Inc.
- 15.7. Replimune Group, Inc.
- 15.8. Oncolys Biopharma, Inc.
- 15.9. Sorrento Therapeutics, Inc.
- 15.10. Oncolytics Biotech, Inc.
- 15.11. Sillajen, Inc.
- 16. Our Research Methodology
- 16.1. Data Triangulation
- 16.2. Data Sources
- 16.2.1. Secondary Sources
- 16.2.2. Primary Sources
- 16.3. Assumptions/ Limitations For The Study
- 16.4. Research & Forecasting Methodology
- 17. Appendix
- 17.1. Disclaimer
- 17.2. Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
